Maternal And Infant Antipsychotic Study
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Sep 16, 2023
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The Maternal And Infant Antipsychotic Study is designed to understand how different treatments affect pregnant individuals with severe mental illnesses, such as bipolar disorder or psychotic disorders. The study compares those who take antipsychotic medications to those who use other types of medications or none at all. Researchers want to find out if taking these medications makes a difference in the mother's mental health, the health of the baby during pregnancy and after birth, and how the baby develops behaviorally and neurologically.
To qualify for this study, participants must be pregnant and have a severe mental illness, and they should be able to communicate in English, Dutch, or Spanish. During the study, participants will undergo interviews, provide blood samples at delivery, and have their babies evaluated for behavior and brain activity. This research aims to help improve treatment options for pregnant individuals dealing with severe mental health issues, ensuring better outcomes for both mothers and their babies.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant
- * Severe mental illness, including:
- • Psychotic disorder (affective and nonaffective)
- • Bipolar disorder
- • History of psychiatric hospitalization, regardless of diagnosis
- • Able to complete study interviews and measures in English, Dutch, or Spanish
- Exclusion Criteria:
- • Active substance use disorder in pregnancy
- • Insufficiently high-functioning to provide full informed consent and/or participate in study procedures
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Thalia Robakis, MD, PhD
Principal Investigator
Icahn School of Medicine at Mount Sinai
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported